2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2289

Accuracy of the Use of Administrative Diagnostic Codes to Identify Pediatric in-Patient Musculoskeletal Conditions in an African Tertiary Hospital
Abstract Number: 942

ACR/EULAR Remission in RA patients in Clinical Practice – Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry
Abstract Number: 2681

Activated SLE-T Cells Enhance the Interferon-Alpha Production By Plasmacytoid Dendritic Cells Stimulated By RNA-IC
Abstract Number: 2949

Activation of AMP-Activated Protein Kinase (AMPK) By Berberine Limits Both Surgical Knee Instability-Induced and Aging-Related Osteoarthritis in Mice
Abstract Number: 23

Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements
Abstract Number: 2100

Activation of NFkβ Pathways in Sjögren’s Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor
Abstract Number: 1195

Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis
Abstract Number: 3006

Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma
Abstract Number: 2348

Activatory Fc Gamma Receptor IV Plays a Crucial Role in Pathogenesis of Experimental Immune Complex Mediated Chronic Arthritis
Abstract Number: 855

Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Etanercept
Abstract Number: 936

Active Invasion of Periodontal Bacteria into Synovial Joint Exacerbates Collagen-Induced Arthritis in Disease-Prone B10 Riii Mice
Abstract Number: 693

Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea
Abstract Number: 2203

Adalimumab Therapy Improves Insulin Sensitivity in Non-Diabetic Psoriatic Patients: A 6-Month Prospective Study
Abstract Number: 2509

ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis
Abstract Number: 1028

ADAM-10 Plays Monocyte Migration and Adhesion in Rheumatoid Arthritis Synovial Fibroblasts

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].